Fractional Chief Marketing Officer

Renue Medical Centre operates regenerative medicine clinics in Nuevo Vallarta and Tijuana, and is expanding to become one of very few facilities globally offering autologous iPSC therapy with an on-site production lab. The company recently closed a growth round and has an existing patient base - this role is about scaling demand, not building from scratch.

The Fractional CMO will own the full demand engine, working directly inside ad accounts and analytics platforms alongside Patient Advisors. The focus is cross-border, cash-pay patient acquisition for a high-consideration, high-ticket category requiring a trust-led marketing approach suited to the US and Canadian markets.

• Own end-to-end patient acquisition across paid media, SEO, content, lifecycle, and partnership channels
• Manage ad accounts and GA4 directly, not at a strategic remove
• Develop and execute the trust-and-transparency narrative for cross-border, cash-pay care
• Collaborate with Patient Advisors to optimise conversion across the full patient journey
• Drive growth across clinic locations in Nuevo Vallarta and Tijuana targeting US and Canadian patients
• Identify and activate relevant partnership and referral channels appropriate to the regenerative medicine category

• Direct, hands-on experience running patient acquisition for a regenerative medicine, stem cell, longevity, fertility, or high-ticket cash-pay clinic
• Deep understanding of the high-consideration, spouse-involved purchase decision in premium healthcare
• Proven ability to manage paid media and SEO in a medically adjacent, ad-policy-restricted environment
• Experience with cross-border patient marketing targeting US patients at international clinic facilities is a strong advantage
• Comfortable working part-time (10 to 20 hours per week) in an operator capacity with performance-based compensation

Renue Medical Centre is a regenerative medicine operator running clinics in Nuevo Vallarta and Tijuana. The business is in an active growth phase, having recently closed a funding round, and is developing on-site iPSC therapy production capability to support its clinical expansion.